leadf
logo-loader
viewOnconova Therapeutics

Onconova Therapeutics anticipates positive pivotal trial readout by the first half of 2020

Onconova Therapeutics Inc (NASDAQ:ONTX) Dr. Steven M. Fruchtman sat down with Proactive’s Christine Corrado at the BIO CEO & Investor Conference in New York.

The Phase 3-stage biopharmaceutical company is focused on discovering and developing small molecule drug candidates to treat cancer, with a focus on myelodysplastic syndromes (MDS).

Quick facts: Onconova Therapeutics

Price: 0.2479 USD

NASDAQ:ONTX
Market: NASDAQ
Market Cap: $45.51 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Mirasol Resources Interim CEO has a vision for the company as he looks to...

Mirasol Resources (CVE: MRZ-OTCPK: MRZLF) CEO Patrick Evans joined Steve Darling from Proactive to provide his thought on the company as their new CEO. He provides views with a background on himself and why he took on the role. Evans also told Proactive about where their strong stable of...

9 hours, 7 minutes ago

2 min read